Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of bempedoic acid + ezetimibe fixed-dose combination versus bempedoic acid alone or ezetimibe alone in statin-treated hypercholesterolemia
CTR20262937Phase 3Active
- Sponsor
- Jiangxi Shimei Pharmaceutical
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bempedoic acid, ezetimibe in hypercholesterolemia, sponsored by Jiangxi Shimei Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
bempedoic acidezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on CTR20262937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262937.